XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 34,392,404 $ 14,310,862
Short-term investments 76,029,116 130,982,913
Accounts receivable from affiliated entities 1,773,665 2,405,228
Prepaid expenses and other current assets 5,365,860 5,393,665
Prepaid expenses and other current assets from affiliated entities 0 20,432
Total current assets 117,561,045 153,113,100
Fixed assets, net 4,510,869 4,960,986
Investment in affiliated entity 2,319,975 2,780,287
Operating lease right-of-use assets 8,819,399 9,491,735
Other assets 585,915 605,315
Total assets 133,797,203 170,951,423
Current liabilities:    
Accrued clinical trial expenses 5,499,648 2,365,382
Operating lease liability 2,321,984 2,406,522
Grant funding liability 0 87,489
Grant funding liability from affiliated entity 21,918 21,918
Convertible senior notes 0 16,770,654
Total current liabilities 26,399,768 42,570,228
Operating lease liability, net of current portion 10,658,228 11,032,066
Total liabilities 37,057,996 53,602,294
Stockholders’ equity:    
Preferred stock 0 0
Common stock 25,962 22,792
Additional paid-in capital 1,783,074,886 1,740,954,074
Accumulated deficit (1,685,672,105) (1,622,965,136)
Accumulated other comprehensive loss (689,536) (662,601)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 96,739,207 117,349,129
Total liabilities and stockholders’ equity 133,797,203 170,951,423
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 16,634,761 19,847,744
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 1,921,457 $ 1,070,519